Scinai Immunotherapeutics Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Public

  • Employees
  • 33

Employees

  • Stock Symbol
  • SCNI

Stock Symbol

  • Share Price
  • $0.50
  • (As of Thursday Closing)

Scinai Immunotherapeutics General Information

Description

BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.

Contact Information

Website
www.scinai.com
Formerly Known As
Biondvax Pharmaceuticals Ltd
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Other Industries
Other Healthcare Services
Stock Exchange
NAS
Corporate Office
  • Jerusalem BioPark Building, 2nd Floor
  • Hadassah Ein Kerem Campus
  • Jerusalem
  • Israel
+972 00-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Scinai Immunotherapeutics Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.50 $0.48 $0.46 - $2.44 $2.18M 4.35M 23.7K -$4.40

Scinai Immunotherapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 21,219 14,721 54,754 58,621
Revenue 0 0 0 0
EBITDA (10,291) (10,499) (10,391) (261)
Net Income (9,286) (5,796) (8,206) (1,294)
Total Assets 18,582 27,067 32,036 17,699
Total Debt 19,807 21,542 28,985 20,887
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Scinai Immunotherapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Scinai Immunotherapeutics‘s full profile, request access.

Request a free trial

Scinai Immunotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing inn
Pharmaceuticals
Jerusalem, Israel
33 As of 2022
000.00
000000000 000.00

000000

ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
0000000000000
Somerville, MA
000 As of 0000
00000
00000000 00000

000000

e eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt
0000 000000000
Abingdon, United Kingdom
00 As of 0000
0000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Scinai Immunotherapeutics Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bluebird Bio Formerly VC-backed Somerville, MA 000 00000 00000000 00000
aVaxziPen Corporation Abingdon, United Kingdom 00 0000000000
Genocea Biosciences Formerly VC-backed Cambridge, MA 00 00000 000000000000
VBI Vaccines Corporate Backed or Acquired Canada 00 000.00 00000000 000.00
Idera Pharmaceuticals Corporation Exton, PA 00 00000 000000000 00000
You’re viewing 5 of 9 competitors. Get the full list »

Scinai Immunotherapeutics Patents

Scinai Immunotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10426828-B2 Compositions of multimeric-multiepitope influenza polypeptides and their production Active 03-Apr-2014 000000000 00
US-20200000910-A1 Compositions of multimeric-multiepitope influenza polypeptides and their production Inactive 03-Apr-2014 0000000000
AU-2015242154-B2 Compositions of multimeric-multiepitope influenza polypeptides and their production Inactive 03-Apr-2014 000000000 0
EP-3125931-A1 Compositions of multimeric-multiepitope influenza polypeptides and their production Pending 03-Apr-2014 000000000
CA-2944768-A1 Compositions of multimeric-multiepitope influenza polypeptides and their production Active 03-Apr-2014 A61K39/12
To view Scinai Immunotherapeutics’s complete patent history, request access »

Scinai Immunotherapeutics Executive Team (9)

Name Title Board Seat Contact Info
Amir Reichman Chief Executive Officer & Board Member
Uri Ben-Or Chief Financial Officer
Elad Mark Chief Operating Officer, Operations
Moran Fruchter Chief of Staff
Tamar Ben-Yedidia Ph.D Chief Scientific Officer
You’re viewing 5 of 9 executive team members. Get the full list »

Scinai Immunotherapeutics Board Members (7)

Name Representing Role Since
0000 00000000 Scinai Immunotherapeutics Chief Executive Officer & Board Member 000 0000
00000 000000 00.0 Scinai Immunotherapeutics Board Member 000 0000
0000 0000000 Scinai Immunotherapeutics Chairman & Board Member 000 0000
000000 000000 00 Self Board Member 000 0000
000000 0000 Scinai Immunotherapeutics Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Scinai Immunotherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Scinai Immunotherapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Scinai Immunotherapeutics‘s full profile, request access.

Request a free trial

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »